Original Wu Yue Minenet
Highlights
On May 8, China Resources Shuanghe announced that the lidocaine hydrochloride injection of its wholly-owned subsidiary, China Resources Shuanghe Limin Pharmaceutical (Jinan), was approved for marketing. Since the beginning of this year, China Resources Shuanghe and its subsidiaries have approved 6 new products, involving five categories.
Table 1: Approved products
Source: Company announcement, compiled by Minenet
It is reported that lidocaine hydrochloride injection is a local anesthetic and antiarrhythmic drug, which is mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block, and can also be used for ventricular premature contractions and ventricular tachycardia after acute myocardial infarction, and can also be used for digitalis poisoning, cardiac surgery and ventricular arrhythmia caused by cardiac catheterization.
According to data from Minenet, more than 90 domestic pharmaceutical companies have obtained production approvals, and only 30 companies have been evaluated/deemed to have been evaluated.
Figure 1: Sales of lidocaine hydrochloride injection (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
At the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), the sales peak of lidocaine hydrochloride injection reached 880 million yuan in 2022, and after the implementation of the seventh batch of national procurement, the sales scale of the product in 2023 fell by 11.35% to about 780 million yuan.
In December 2022, China Resources Shuanghe Limin Pharmaceutical (Jinan) submitted a Type 3 generic marketing application for lidocaine hydrochloride injection, which was approved in April 2024 and deemed to have passed the evaluation. The announcement mentioned that the company has carried out generic research on the drug, and the cumulative R&D investment is about 3.7 million yuan.
Table 2: New products approved by CR Shuanghe and its subsidiaries this year
Source: Minenet China Declaration Progress (MED) database
Since the beginning of this year, CR Shuanghe and its subsidiaries have approved 6 new products, all of which are chemical drugs, involving five categories: digestive system and metabolic drugs, blood and hematopoietic system drugs, cardiovascular and cerebrovascular system drugs, nervous system drugs, and systemic anti-infective drugs.
Source: Minenet database, company announcements
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of May 9, if there is any omission, please correct!